Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | WVT078 |
| Synonyms | |
| Therapy Description |
WVT078 is a bispecific antibody that targets the B-cell maturation antigen (BCMA; TNFRSF17) expressed on tumor cells and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and killing of BCMA-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| WVT078 | WVT-078|WVT 078 | CD3 Antibody 119 TNFRSF17 Antibody 22 | WVT078 is a bispecific antibody that targets the B-cell maturation antigen (BCMA; TNFRSF17) expressed on tumor cells and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and killing of BCMA-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04123418 | Phase I | WVT078 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Terminated | USA | NOR | ITA | ISR | ESP | DEU | AUS | 1 |